Biomea Fusion Status Update: Experts Discuss Icovamenib’s Promise Ahead of ADA 2026

Key Points

• Icovamenib has shown encouraging early signals of beta‑cell restoration—type 1 data reported a 52% mean C‑peptide increase at week 12 with limited decline by week 52, and type 2 data showed roughly 1.2–1.5 point A1C reductions and 24–35% C‑peptide increases at 52 weeks.
• Safety, durability and PK/PD remain the central unknowns: experts highlight the need for longer follow‑up and larger trials to rule out MEN1‑related tumor risk and to confirm true, sustained beta‑cell regeneration rather than a transient drug effect.
• Clinically and commercially, a short (12–24 week) regenerative course that combines with or augments GLP‑1s—especially for insulin‑using or leaner type 2 patients—could differentiate the drug, and Rodman & Renshaw currently rates Biomea a buy with an $8 target.

Rodman & Renshaw Director of Research Michael King hosted an endocrinology-focused discussion with Dr. Alexander Abitbol, an endocrinologist and assistant medical director at LMC Healthcare, ahead of the American Diabetes Association (ADA) meeting in New Orleans. The conversation centered on treatment trends in type 1 and type 2 diabetes and focused in particular on Biomea Fusion NASDAQ: BMEA and its investigational menin inhibitor, icovamenib.

King disclosed that Rodman & Renshaw rates Biomea shares a buy with an $8 price target and said neither he nor his household owns the stock. Abitbol disclosed that he has received investigator fees for clinical trials supported by Biomea and serves as an advisor and consultant to Biomea and “all of the major pharmaceutical companies” involved in diabetes and cardiovascular-related therapies, including GLP-1s, SGLT2 inhibitors, DPP4s, and lipid-lowering medications.

Clinical setting: how diabetes care is evolving with GLP-1s

Abitbol described his practice at LMC Healthcare, a multisite endocrinology group across 11 locations primarily in Ontario, Canada, with an additional site in Calgary. He said that roughly 50% to 60% of his general endocrine patients have diabetes, with about 80% to 85% of those having type 2 diabetes and about 10% to 15% having type 1 diabetes.

In clinic, Abitbol said he typically sees 30 to 35 patients per day, mostly follow-ups, with five to eight new referrals. He characterized referrals as varying by geography: in urban Toronto, patients may be referred earlier for specialist access and support services, while in more remote or suburban communities, primary care physicians may manage patients longer before referring once treatment options narrow or comorbidities complicate management.

Abitbol said GLP-1 adoption has accelerated compared with prior eras. Patients increasingly request therapies they “see advertised on the internet” or through social circles, which he said pushes primary care to adopt newer agents and technology faster than the historical five-to-seven-year diffusion curve.

Type 2 diabetes: GLP-1 use, insulin use, and “treatment failure” over time

Abitbol provided estimates of current treatment patterns in specialty care versus primary care. In his specialty practice, he said GLP-1 usage runs around 35% to 40%, while population-level rates across all type 2 diabetes patients are closer to 15% to 20%.

On insulin, Abitbol said that “across the lifespan, somebody with diabetes will need insulin 50% of the time,” adding that in his specialty practice about 50% to 60% of patients are treated with insulin. Within that insulin-treated group, he said roughly 20% use multiple daily injections and about 40% use basal insulin only. In primary care, he estimated insulin-treated patients are more commonly in the 10% to 20% range.

Abitbol also said he is seeing more referrals of type 2 diabetes patients who are already on GLP-1 therapy and are seeking next steps due to inadequate glycemic control, weight-loss plateaus, or tolerability issues. In his Toronto office, he estimated about 30% of referrals arrive on GLP-1s, while in Oakville, where he described a “very savvy GP population,” he said 60% to 65% arrive on GLP-1s because primary care has managed them longer before referring.

While King asked about relapse or inadequate response rates after six to 12 months of GLP-1 therapy, Abitbol framed the issue as the progressive nature of diabetes. “If you manage a patient for long enough…they will eventually need another agent,” he said, adding that even with potent therapies, many patients later need additional drugs for glycemic control or further weight loss.

Icovamenib’s mechanism: beta-cell biology, durability, and safety questions

King and Abitbol discussed icovamenib’s approach as distinct from glucose-lowering drugs that act via liver glucose output, renal glucose excretion, or insulin secretion dynamics without restoring beta-cell mass. Abitbol said what attracted him is the possibility of intervening in an “underlying disease process” affecting beta-cell function and number, which he described as a core driver of diabetes progression.

King referenced prior work suggesting menin is involved in beta-cell expansion during pregnancy and lactation. Abitbol characterized menin as a broadly present “brake” on cell growth and proliferation, and said inhibiting it could enable cellular expansion and potentially restore beta-cell capacity. He also noted the target’s history in oncology, describing how the pathway drew attention due to relevance in cellular growth processes in cancers such as acute myeloid leukemia.

On patient acceptance, Abitbol suggested a potential clinical narrative could involve a time-limited course—“between 12 and 24 weeks”—intended to allow pancreatic regeneration and produce durable glucose improvements after stopping therapy. He contrasted that with lifelong medication escalation and suggested that, in theory, such an approach could delay additional agents and potentially reduce background medications, including insulin doses.

Abitbol said a key initial concern for endocrinologists is safety, noting the MEN1 gene’s association with neuroendocrine tumors when mutated. He said he was reassured by safety monitoring in trials and by the distinction between pharmacologic inhibition in a disease context versus congenital loss-of-function mutations. He added that the oncology experience with menin inhibition did not show new tumors forming during treatment.

Regarding hypoglycemia risk, Abitbol said the glucose-dependent nature of endogenous insulin responses should be protective, noting that in icovamenib studies hypoglycemia was not prominent, while also acknowledging that patients on agents most associated with hypoglycemia or insulin were excluded.

On durability, Abitbol attributed any sustained effect after stopping therapy to the mechanism itself—regenerating and expanding beta-cell mass—rather than a drug effect that depends on continuous exposure and half-life, as is the case with metformin, SGLT2 inhibitors, and other agents.

Type 1 diabetes: interpreting C-peptide data and the need for longer-term clinical endpoints

King asked Abitbol to react to Biomea’s COVALENT-112 type 1 diabetes data, describing 52-week results that included a 52% increase in mean C-peptide at week 12 after a 12-week course, with a 7% decline from peak to week 52 in the 200 mg group. Abitbol called his reaction “generally positive,” while emphasizing he wanted additional information—particularly pharmacokinetic/pharmacodynamic (PK/PD) context and explanations for non-responders.

He noted that type 1 diabetes is heterogeneous and said the clinical implications would depend on endpoints beyond C-peptide, including insulin dose and long-term complications. Still, he said he would prioritize C-peptide over A1C in type 1 diabetes: “The C-peptide is the biggest predictor of complications,” he said, describing residual endogenous insulin production as a “parachute” that can reduce glycemic volatility and make patients easier to manage.

Abitbol also discussed type 1 staging and the practical challenges of identifying earlier-stage patients (stage 1 or stage 2) outside of research registries. He said he is “very excited” about a therapy aimed at stage 3 type 1 diabetes because that is what clinicians most commonly detect and treat in routine practice.

What Abitbol will watch for at ADA and in future trial designs

Looking ahead to ADA, Abitbol said that as an early-phase investigator he will be focused on safety—treatment-emergent adverse events, liver and kidney parameters, and neuroendocrine hormone signals—alongside efficacy readouts such as C-peptide, A1C, hypoglycemia rates, and insulin-dose changes.

He also commented on a proposed type 1 study design King described involving an initial placebo-controlled icovamenib monotherapy period followed by re-randomization to different arms including an immunosuppressant (baricitinib, a JAK inhibitor). Abitbol called the trial “very challenging and a huge undertaking,” noting it would require substantial patient numbers and might show “small differences” after crossover, but added that it is the type of study “everybody will wanna read” because it tests both placebo separation and durability with or without immune modulation.

In type 2 diabetes, King cited COVALENT-111 results he summarized as A1C reductions of roughly 1.2 to 1.5 percentage points and C-peptide increases of 24% to 35% at 52 weeks. Abitbol said that magnitude of A1C lowering would be clinically meaningful if replicated in later-stage trials, emphasizing that many approved agents have smaller effects. He also highlighted that icovamenib’s potential differentiation would be short-term treatment rather than continuous therapy.

When asked what it would take for icovamenib to stand out in a GLP-1-dominated landscape, Abitbol pointed to combination potential, including enhancing GLP-1 effects, and said differentiation could come from demonstrating benefit in insulin-using type 2 patients or leaner type 2 populations not typically prioritized for GLP-1s. He also discussed the prospect of a “generic semaglutide world,” saying that if a menin inhibitor could augment a lower-cost GLP-1, it could be a compelling proposition for clinicians and patients.

About Biomea Fusion NASDAQ: BMEA

Biomea Fusion, Inc NASDAQ: BMEA is a clinical‐stage biopharmaceutical company headquartered in Carlsbad, California. The company is dedicated to the discovery and development of small molecule therapies that target epigenetic regulators implicated in cancer. By leveraging a proprietary chemistry and drug discovery platform, Biomea Fusion aims to design precision medicines that modulate gene expression pathways involved in the initiation and progression of hematological malignancies and solid tumors.

The company's lead clinical asset, BMF-219, is an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.